attention deficit disorder

April 2, 2021

Study links ADHD pharmacotherapy and retention rates for substance use disorder treatment

Kristopher Kast, MD, assistant professor in the Department of Psychiatry and Behavioral Sciences and clinical director of Vanderbilt’s Addiction Consult Service, has discovered a strong association between attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy and retention rates for substance use disorder (SUD) treatment.

By Emily Stembridge
William Cooper
November 2, 2011

Vanderbilt study finds no heart risk in ADHD medications

Attention Deficit Hyperactivity Disorder (ADHD) medications do not increase the risk for heart disease or heart attack in children and young adults, according to a Vanderbilt study of 1.2 million patients taking drugs including Ritalin, Adderall, Concerta and Strattera between 1998 and 2005.

By VUMC News and Communications